Graft localized drug delivery to augment beta cell replacement therapies for diabetes

移植局部药物递送以增强糖尿病的β细胞替代疗法

• 批准号: 480374
• 负责人: Pepper Andrew R
• 金额: $ 78.86万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-03-01 至 2028-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=480374&lang=en
• 关键词: Beta Cells; Biomaterials; Cell Thearpies; Diabetes; Immunosuppression; Insulin; Islets; Transplantation

Type 1 diabetes (T1D) occurs when islet cells in the pancreas lose the ability to regulate the amount of glucose (sugar) in the blood. Diabetes affects more than 10 million Canadians and costs our health care system more than $30 billion each year. The go

当胰腺中的胰岛细胞失去调节血液中葡萄糖含量的能力时，就会发生 1 型糖尿病 (T1D)。糖尿病影响着超过 1000 万加拿大人，每年给我们的医疗保健系统造成超过 300 亿加元的损失。去吧